-
2023-505604-32-00
5
2024-01-24
Non small cell lung cancer (NSCLC)
-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2022-501703-27-00
5
2023-07-05
Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2024-511267-28-00
5
2021-02-17
B-cell malignancies
-
2024-517337-41-00
5
2026-05-12
Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
-
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
-
2025-522979-29-00
5
2026-04-30
Acute myeloid leukemia
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-513174-22-00
4
2026-04-14
Atrophic Age-related Macular Degeneration (AMD)
-
2025-521416-19-00
4
2026-03-12
Recurrence of Clostridioides difficile Infection
-
2025-523075-32-00
5
2026-03-09
chronic kidney disease
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2025-522701-38-00
6
2026-02-26
SUBRETINAL HYPERREFLECTIVE MATERIAL
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2025-521873-15-00
9
2026-02-09
Metastatic hormone-sensitive prostate cancer
-
2024-520253-21-00
5
2026-02-02
Chronic Kidney Disease
-
2025-522680-14-00
2
2025-12-23
Chronic Graft-versus-Host Disease
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer